

Maria Chiara Bonini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2764571/publications.pdf>

Version: 2024-02-01

120
papers

12,551
citations

26630

56
h-index

25787

108
g-index

124
all docs

124
docs citations

124
times ranked

14697
citing authors

#	ARTICLE	IF	CITATIONS
1	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. <i>Nature Medicine</i> , 2018, 24, 739-748.	30.7	947
2	Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. <i>Nature Medicine</i> , 2006, 12, 1397-1402.	30.7	593
3	Targeted genome editing in human repopulating haematopoietic stem cells. <i>Nature</i> , 2014, 510, 235-240.	27.8	517
4	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2009, 361, 478-488.	27.0	459
5	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase II study. <i>Lancet Oncology</i> , 2009, 10, 489-500.	10.7	458
6	IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. <i>Blood</i> , 2013, 121, 573-584.	1.4	455
7	A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. <i>Blood</i> , 2012, 119, 5697-5705.	1.4	437
8	Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. <i>Blood</i> , 2005, 105, 1162-1169.	1.4	435
9	Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. <i>Nature Medicine</i> , 2012, 18, 807-815.	30.7	398
10	T memory stem cells in health and disease. <i>Nature Medicine</i> , 2017, 23, 18-27.	30.7	396
11	CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. <i>Blood</i> , 2013, 122, 3461-3472.	1.4	306
12	Site-specific integration and tailoring of cassette design for sustainable gene transfer. <i>Nature Methods</i> , 2011, 8, 861-869.	19.0	300
13	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	30.7	253
14	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218
15	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
16	The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. <i>Blood</i> , 2007, 109, 4708-4715.	1.4	200
17	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	2.4	196
18	Enhancing anti-tumour efficacy with immunotherapy combinations. <i>Lancet</i> , 2021, 397, 1010-1022.	13.7	196

#	ARTICLE	IF	CITATIONS
19	A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. <i>Blood</i> , 2003, 103, 1417-1424.	1.4	195
20	ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. <i>Journal of Biology</i> , 2006, 5, 14.	2.7	185
21	Herpes Simplex Virus Thymidine Kinase Gene Transfer for Controlled Graft-versus-Host Disease and Graft-versus-Leukemia: Clinical Follow-up and Improved New Vectors. <i>Human Gene Therapy</i> , 1998, 9, 2243-2251.	2.7	178
22	Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1457-1462.	7.1	172
23	Antitumor effects of HSV-TKâ€“engineered donor lymphocytes after allogeneic stem-cell transplantation. <i>Blood</i> , 2007, 109, 4698-4707.	1.4	171
24	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	166
25	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. <i>Blood</i> , 2018, 131, 247-262.	1.4	164
26	In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. <i>Science Translational Medicine</i> , 2015, 7, 273ra13.	12.4	160
27	IL-7 and IL-15 allow the generation of suicide geneâ€“modified alloreactive self-renewing central memory human T lymphocytes. <i>Blood</i> , 2009, 113, 1006-1015.	1.4	153
28	Intraâ€“arterial transplantation of <sc>HLA</sc> â€“matched donor mesoangioblasts in Duchenne muscular dystrophy. <i>EMBO Molecular Medicine</i> , 2015, 7, 1513-1528.	6.9	146
29	Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. <i>Blood</i> , 2003, 102, 497-505.	1.4	142
30	Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy. <i>Human Gene Therapy</i> , 1995, 6, 813-819.	2.7	137
31	The Suicide Gene Therapy Challenge: How to Improve a Successful Gene Therapy Approach. <i>Molecular Therapy</i> , 2007, 15, 1248-1252.	8.2	131
32	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	125
33	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1506-1514.	2.0	121
34	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. <i>Nature Communications</i> , 2019, 10, 1065.	12.8	120
35	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. <i>Blood</i> , 2015, 125, 2865-2874.	1.4	119
36	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , 2018, 53, 1139-1148.	2.4	117

#	ARTICLE	IF	CITATIONS
37	Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. <i>Blood</i> , 2003, 101, 1290-1298.	1.4	115
38	Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 3488-3499.	1.4	113
39	Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. <i>Blood</i> , 2006, 107, 1828-1836.	1.4	110
40	Improving the safety of cell therapy with the TK-suicide gene. <i>Frontiers in Pharmacology</i> , 2015, 6, 95.	3.5	102
41	Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. <i>Science Translational Medicine</i> , 2015, 7, 317ra198.	12.4	102
42	Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+and CD8+T Cells. <i>Journal of Immunology</i> , 2001, 166, 5250-5257.	0.8	101
43	A CD8 ^{hi} Subset of CD4 ⁺ SLAMF7 ⁺ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment. <i>Arthritis and Rheumatology</i> , 2018, 70, 1133-1143.	5.6	87
44	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
45	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
46	A novel self-lipid antigen targets human T cells against CD1c+ leukemias. <i>Journal of Experimental Medicine</i> , 2014, 211, 1363-1377.	8.5	80
47	Transcriptional Enhancers Induce Insertional Gene Deregulation Independently From the Vector Type and Design. <i>Molecular Therapy</i> , 2009, 17, 851-856.	8.2	79
48	Adoptive T-cell therapy for cancer: The era of engineered T cells. <i>European Journal of Immunology</i> , 2015, 45, 2457-2469.	2.9	75
49	Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene. <i>Frontiers in Immunology</i> , 2018, 9, 507.	4.8	73
50	NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. <i>Blood</i> , 2017, 130, 606-618.	1.4	71
51	Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. <i>Frontiers in Immunology</i> , 2020, 11, 1217.	4.8	69
52	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	66
53	Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Human Gene Therapy</i> , 2010, 21, 241-250.	2.7	63
54	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. <i>Frontiers in Immunology</i> , 2020, 11, 1689.	4.8	63

#	ARTICLE	IF	CITATIONS
55	Changes in the Immune Responses Against Human Herpesvirus-8 in the Disease Course of Posttransplant Kaposi Sarcoma. <i>Transplantation</i> , 2008, 86, 738-744.	1.0	62
56	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. <i>Frontiers in Immunology</i> , 2017, 8, 1444.	4.8	62
57	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2365-2370.	2.0	61
58	A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. <i>Blood</i> , 2001, 97, 1249-1257.	1.4	59
59	Transfection of RNA Encoding Tumor Antigens Following Maturation of Dendritic Cells Leads to Prolonged Presentation of Antigen and the Generation of High-Affinity Tumor-Reactive Cytotoxic T Lymphocytes. <i>Molecular Therapy</i> , 2004, 9, 757-764.	8.2	58
60	Frequency and Targeted Detection of HLA-DPB1 T Cell Epitope Disparities Relevant in Unrelated Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1031-1040.	2.0	50
61	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 120, 1820-1830.	1.4	47
62	Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. <i>Science Translational Medicine</i> , 2022, 14, eabg3072.	12.4	47
63	Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. <i>Immunological Reviews</i> , 2014, 257, 165-180.	6.0	46
64	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014, 75, 447-453.	5.3	43
65	Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. <i>Blood</i> , 2012, 119, 4813-4815.	1.4	42
66	IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. <i>Blood</i> , 2011, 117, 6469-6478.	1.4	40
67	High-Definition Mapping of Retroviral Integration Sites Defines the Fate of Allogeneic T Cells After Donor Lymphocyte Infusion. <i>PLoS ONE</i> , 2010, 5, e15688.	2.5	39
68	Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. <i>Oncotarget</i> , 2015, 4, e1005460.	4.6	37
69	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2250-2255.	2.0	36
70	Genetic Modification of T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S15-S20.	2.0	30
71	Use of TK-cells in haploidentical hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2012, 19, 427-433.	2.5	30
72	Early Reconstitution of T-Cell Immunity to CMV After HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is a Strong Surrogate Biomarker for Lower Non-Relapse Mortality Rates. <i>Blood</i> , 2012, 120, 4191-4191.	1.4	28

#	ARTICLE	IF	CITATIONS
73	CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade. <i>Arthritis and Rheumatology</i> , 2020, 72, 565-575.	5.6	27
74	A dual role for genetically modified lymphocytes in cancer immunotherapy. <i>Trends in Molecular Medicine</i> , 2012, 18, 193-200.	6.7	26
75	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 776.e1-776.e13.	1.2	26
76	Concomitant Tumor and Minor Histocompatibility Antigen-Specific Immunity Initiate Rejection and Maintain Remission from Established Spontaneous Solid Tumors. <i>Cancer Research</i> , 2010, 70, 3505-3514.	0.9	25
77	Genetically Modified Donor Leukocyte Transfusion and Graft-Versus-Leukemia Effect After Allogeneic Stem Cell Transplantation. <i>Human Gene Therapy</i> , 2011, 22, 829-841.	2.7	25
78	Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1 Acute Myeloid Leukemia. <i>Human Gene Therapy</i> , 2013, 24, 220-237.	2.7	24
79	Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene. <i>Molecular Therapy</i> , 2013, 21, 466-475.	8.2	23
80	CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. <i>Science Translational Medicine</i> , 2022, 14, eabg8027.	12.4	21
81	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
82	Inflammation Converts Human Mesoangioblasts Into Targets of Alloreactive Immune Responses: Implications for Allogeneic Cell Therapy of DMD. <i>Molecular Therapy</i> , 2014, 22, 1342-1352.	8.2	20
83	Predicting the Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: The Long and Winding Road toward Validated Immune Biomarkers. <i>Frontiers in Immunology</i> , 2013, 4, 71.	4.8	18
84	Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 772239.	4.8	18
85	Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells. <i>Frontiers in Pharmacology</i> , 2015, 6, 76.	3.5	17
86	Therapeutic and Diagnostic Applications of Minor Histocompatibility Antigen HA-1 and HA-2 Disparities in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey of Different Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 95-101.	2.0	16
87	Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. <i>Blood</i> , 2005, 105, 3596-3604.	1.4	15
88	Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition. <i>Human Gene Therapy</i> , 2015, 26, 220-231.	2.7	15
89	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. <i>American Journal of Hematology</i> , 2017, 92, 1011-1019.	4.1	14
90	Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. <i>Cytotherapy</i> , 2018, 20, 453-460.	0.7	14

#	ARTICLE	IF	CITATIONS
91	Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. <i>Current Opinion in Oncology</i> , 2020, 32, 427-433.	2.4	13
92	Expression of HSV-TK suicide gene in primary T lymphocytes: The dog as a preclinical model. <i>Cytokines, Cellular & Molecular Therapy</i> , 2000, 6, 25-33.	0.3	10
93	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. <i>Bone Marrow Transplantation</i> , 2018, 53, 1201-1205.	2.4	10
94	Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells. <i>European Journal of Immunology</i> , 2021, 51, 1992-2005.	2.9	10
95	Overcoming key challenges in cancer immunotherapy with engineered T cells. <i>Current Opinion in Oncology</i> , 2020, 32, 398-407.	2.4	9
96	Application of Donor Lymphocytes Expressing a Suicide Gene for Early GVL Induction and Later Control of GVH Reactions After Bone-Marrow Transplantation. , 2005, 109, 475-486.		8
97	Changes in T-Cell Responses Against Human Herpesvirus-8 Correlate with the Disease Course of Iatrogenic Kaposi's Sarcoma in a Patient with Undifferentiated Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 39, 170-175.	3.4	8
98	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. <i>Bone Marrow Transplantation</i> , 2019, 54, 867-876.	2.4	8
99	Retrovirus mediated gene transduction of human T-cell subsets. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 759-768.	4.2	6
100	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1548-1552.	2.4	6
101	Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1937-1943.	3.0	6
102	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2018, 53, 722-728.	2.4	5
103	Rapid and Wide Immunoreconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT.. <i>Blood</i> , 2006, 108, 307-307.	1.4	4
104	1107. Gene Therapy Clinical Trials for Relapsed Leukemia with Infusions of the Suicide-Gene Transduced Donor Lymphocytes in Japan. <i>Molecular Therapy</i> , 2006, 13, S426.	8.2	3
105	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. <i>Nature Communications</i> , 2021, 12, 4844.	12.8	3
106	Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication. <i>Blood</i> , 2012, 120, 949-949.	1.4	3
107	Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> . 2016. 128. 4599-4599.	1.4	3
108	Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells. <i>Blood</i> , 2013, 122, 142-142.	1.4	2

#	ARTICLE	IF	CITATIONS
109	Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases. <i>Life Science Alliance</i> , 2022, 5, e202101316.	2.8	2
110	When transgenes shape immunity: cancer immune gene therapy. <i>Journal of Gene Medicine</i> , 2012, 14, 384-385.	2.8	1
111	TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD. <i>Blood</i> , 2011, 118, 667-667.	1.4	1
112	NLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL. <i>Blood</i> , 2020, 136, 32-33.	1.4	1
113	Potential of Gene Therapy in Bone Marrow Transplantation. <i>BioDrugs</i> , 1999, 11, 1-6.	4.6	0
114	The hidden (and lazy) TCR. <i>Blood</i> , 2009, 114, 2855-2856.	1.4	0
115	Trick to treat: tricking the thymus to treat cancer. <i>Blood</i> , 2013, 122, 304-306.	1.4	0
116	Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia.. <i>Blood</i> , 2010, 116, 3764-3764.	1.4	0
117	An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT. <i>Blood</i> , 2015, 126, 1929-1929.	1.4	0
118	Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults. <i>Blood</i> , 2015, 126, 4362-4362.	1.4	0
119	Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants. <i>Blood</i> , 2015, 126, 5465-5465.	1.4	0
120	Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory. <i>Blood</i> , 2015, 126, 263-263.	1.4	0